In this study, we identified five novel polymorphisms in the estrogen receptor beta (ERb) gene in an African population. Interestingly, two of these variants are expected to change the amino acid sequence of the ERb protein. These changes correspond to an isoleucine to valine substitution at amino acid position 3 (I3V) and a valine to glycine substitution at position 320 (V320G), respectively. The functional consequences of these amino acid substitutions were determined in different in vitro assays. The I3V mutation displayed no differences with regard to transcriptional activity in a reporter assay, as compared with the wildtype receptor. The V320G mutation, however, showed significantly decreased maximal transcriptional activity in a reporter assay, although its binding affinity for 17b-estradiol was not affected. A pull-down assay indicated that the interaction of full-length TIF2 with hERbV320G was weaker than with hERbwt. Moreover, surface plasmon resonance analysis revealed reduced interaction of the V320G ERb variant with the NR box I and II modules of TIF2. To our knowledge, this represents the first identification of a functional polymorphism in the ERb gene. This novel polymorphism provides a tool for human genetic studies of diseases in the African population.
Introduction
Estrogen receptors (ERs) belong to the steroid/retinoid receptor gene superfamily, which contains the receptors for glucocorticoids, mineralocorticoids, progesterone, androgen, thyroid hormone, vitamin D and retinoic acid. As a family, its members share some structural and functional similarities including four functional domains. From the N-terminus to the C-terminus of the receptor molecule, these are: the A/B region that contributes to the transcriptional activation function; the C-region, or the DNA-binding domain, that harbors the DNAbinding function mediating specific DNA binding; the hinge region followed by the ligand-binding domain (the LBD or the E/F domain). The LBD harbors the ligand-binding pocket as well as sites for co-factor binding, transactivation, nuclear localization and interactions with heat shock proteins (1).
Upon ligand-dependent or -independent activation, these receptors form dimers and modulate transcription by binding to their corresponding hormone response elements (for example ERE, estrogen response element) in the promoter region of target genes (2) . There are two estrogen receptors, ERa and ERb. These two receptors show high homology, particularly in the DNA-binding domain. The receptors are expressed in a distinct but sometimes over-lapping mode and display functional similarities as well as differences, sometimes even opposite actions (3) .
Polymorphisms in ER genes, the major mediators of estrogen signaling, are associated with some endocrine related disorders. Polymorphisms in ERa are associated with breast cancer (4--6), endometrial cancer (7), lupus nephritis (8) , menstrual disorder (9), Alzheimer's disease (10) , osteoporosis (11) and coronary artery disease (12) . Polymorphisms in the ERb gene have been correlated to other pathological states as compared with ERa polymorphisms, such as ovulatory dysfunctions (9) , hypertension (13) , bone mineral density (14) and androgen levels (15) . No data are available regarding polymorphisms in ER genes in African populations.
Several genetic differences have been described between African Americans and white Americans, which may account for the higher incidence of certain diseases in the former population. For example, estrogen metabolism appears to vary according to race, with a higher ratio of inactive:active metabolites in whites compared with blacks (16) . Polymorphisms in some steroid hormone nuclear receptors have been shown to correlate with race related endocrine diseases. For example, short CAG repeat lengths in the androgen receptor gene were found in African Americans and possibly associated with a higher stage of prostate cancer (17) . Polymorphisms in the vitamin D receptor gene are associated with bone mass differences between African Americans and white Americans (18) .
In this investigation we screened the ERb gene in an African population for polymorphisms. Any identified polymorphism, particularly a functional polymorphism, would constitute important tools for further association with diseases.
Materials and methods

Samples
Nigerian healthy blood donors (n ¼ 96 from Banjul, Gambian) were included in the study. Genomic DNA was isolated using standard phenol--chloroform extraction followed by ethanol precipitation. The studies were approved by the ethical committee of the Karolinska Institute.
PCR PCR amplifications were performed in a total volume of 25 ml containing 200 mM dNTPs, 10--50 ng of template DNA, 0.4 mM each of primers, 1.25 U Taq DNA polymerase (Roche, Mannheim, Germany), in 1Â reaction buffer (10 mM Tris--HCl pH 8.3, 50 mM KCl, 2.5 mM MgCl 2 ). Primer sequences to amplify the ERb gene were designed based on the published GenBank ERb gene sequence NT_025892 (Table I) . PCR amplification was carried out at 94 C for 10 min followed by 35 cycles (94 C for 30 s, 57--60 C for 30 s and 72 C for 45 s), and finally 10 min at 72 C.
Denaturing high-performance liquid chromatography (DHPLC) PCR products from amplification of genomic DNA from all individuals were analysed using DHPLC on a WAVE DNA Fragment Analysis System (Transgenomic, Cheshire, UK) and DNASep Column as described (19) using the temperature suggested by the WAVEMAKER TM Software package (Transgenomic, Crewe, UK). Prior to DHPLC analysis, PCR products were denatured at 95 C for 5 min and then cooled to 25 C over 45 min to enable the formation of heteroduplexes. Aliquots of 5 ml were automatically loaded on the DNAsep column for heteroduplex analysis.
Samples with aberrant HPLC profiles were subjected to DNA sequencing using ABI Prism Ò BigDye TM Terminator Cycle Sequence Ready Reaction Kit (Applied Biosystems) and compared with the published genomic sequence of the ERb gene. In certain cases, Restriction Fragment Length Polymorphism analysis was used to confirm polymorphisms. FokI was used to score 105A!G, RsaI was used to score 1082G!A, AluI was used to score1730G!A and Van91I was used to score 1057T!G.
Generation of human ERb plasmids containing the 105A!G or 1057T!G mutations A wild-type pSG5-hERb plasmid was a gift from Dr Michel Tujague at the Department of Biosciences, Karolinska Institute. hERb plasmids that incorporate the identified amino acid changes of the ERb gene were created from the wild-type hERb530 plasmid using the QuickChange TM XL Site-Directed mutagenesis kit (Stratagene, La Jolla, CA) according to the instruction manual. DNA sequencing confirmed the sequences of the mutant clones. The resulting plasmids are named hERb105A!G and hERb1057T!G, respectively.
Transient transfection assays and western blot analysis HEK293 cells were cultured in a 1:1 mixture of Ham's Nutrient mixture F12 (Invitrogen) and DMEM (Invitrogen) supplemented with 5% FBS and 100 U penicillin/ml and 100 mg streptomycin/ml. For transfection, the cells were seeded at a density of 1 Â 10 4 cells/well in 96-well plates and co-transfected with 2Â ERE TK luciferase reporter plasmid (0.4 mg) (20) and the respective ER expression vectors (0.016 mg). A pRL-TK control plasmid, which contains a Renilla luciferase gene, was included to control for differences in transfection efficiencies. The medium was replaced with a phenol red-free mixture of F12 and DMEM containing 5% dextran-coated charcoaltreated FBS and 100 U penicillin/ml and 100 mg streptomycin/ml upon transfection. 17b-Estradiol (0.1, 1, 10, 100 nM) or vehicle (in 0.1% ethanol) was added just after transfection. The cells were harvested 24 h after transfection and luciferase activities were determined using the Dual Luciferase Reporter Assay System (Promega) according to the manufacturer's instructions.
Western blotting was done according to the protocol as described (21) . ERb was detected with an ERb LBD rabbit polyclonal antibody produced by us as described previously (22) . As a positive control, the recombinant human ERb530 protein purchased from Panvera (Madison, WI) was used.
Cloning and expression of hERbwt and hERb1057T!G LBDs
The LBDs (R254 to Q530) were obtained by PCR using full-length cDNAs as templates and primers that contained appropriate restriction sites. hERbwt and hERb1057T!G were cloned into pET15b (Novagen, Madison, WI) to generate proteins with N-terminal His-tags. The sequences of all constructs were verified by DNA sequencing.
Cultures (500 ml) of the Escherichia coli strain BL21, transformed with the appropriate expression plasmids, were cultivated overnight in LB supplemented with 100 mg/ml of ampicillin at 37 C. When the OD600 reached 1.0, IPTG was added to a final concentration of 1 mM and incubation continued for 3 h at 25 C. The cells were pelleted and the supernatant was discarded. The pellet was suspended in 5 ml (one-tenth of the culture volume) of extraction buffer [complete EDTA-free, Roche Diagnostics, Germany, 0.3 M NaCl, 20 mM Tris (pH 8.0), 0.01 mg/ml DNase, 0.01 mg/ml RNase, 10 mM MgCl 2 , 0.25 mg/ml lysozyme, 1 mM b-ME and protease inhibitor cocktail tablet]. The samples were sonicated for 4 min at 50% duty (total sonication time 2 min). The homogenate was centrifuged at 13 000 g for 20 min at 4 C. The supernatant was applied to a TALON metal affinity column (Clontech Laboratories, Palo Alto, CA). Fractions containing the purified protein were dialyzed against 20 mM Tris (pH 8), 150 mM NaCl, 1 mM DTT and frozen at À80 C. The purified protein was 495% pure as determined from Coomassie stained SDS--PAGE gels. The protein concentrations were measured using the Coomassie Protein Assay Kit (Pierce, IL) according to the manufacturer's instructions.
Scintillation proximity assay
The assay was performed in 96-well microplates (PerkinElmer Life Sciences, MA). Polyvinyltoluene copper-loaded his-tag beads were purchased from Amersham. The reaction mixture (60 ml/well) containing assay buffer ( For ligand competition studies, purified ERb LBDs (20 nM) were incubated overnight at 4 C with a range of test compound concentrations. A final concentration of 1.5 nM [
3 H]17b-estradiol (30 ml/well) was used. The ligands were tested three times with similar results. Curve fitting was performed using Prism (GraphPad Software) and the IC 50 s determined. IC 50 values were converted to K i using the Cheng-Prusoff equation,
where D is the concentration of the radioligand (24) .
Pull-down assay
For pull-down assays, purified His-tagged ERb LBDs (100 mg) were bound to 60 ml of Talon resin and then equilibrated in 50 mM Tris--HCl, pH 7.4, 100 mM NaCl, 1 mM MgCl 2 , 10% glycerol and 0.5% NP-40 (equilibration buffer). The gel slurry was then divided into two equal aliquots and to each tube, 2.5 ml of in vitro translated, 35 S-labeled (TNT coupled reticulocyte lysate system, Promega), full-length TIF2 was added in a total volume of 150 ml equilibration buffer containing 1.5% BSA. Estradiol or vehicle (ethanol) was added as indicated. As control, TIF2 was mixed with Talon gel without bound ERb. All samples were incubated for 2 h with gentle shaking at 4 C. After washing three times with equilibration buffer, bound proteins were eluted with SDS--PAGE sample buffer and separated on a 12% polyacrylamide gel. The gel was stained with Coomassie Blue, followed by determination of 35 S using a PhosphoImager instrument.
Surface plasmon resonance (SPR) analysis
All SPR measurements were performed on a BIAcore 2000 instrument (BIAcore AB, Uppsala, Sweden). All experiments were performed at 25 C, and at a flow rate of 5 ml/min. Research grade streptavidin sensor chips were obtained from BIAcore AB. The streptavidin chips were first treated with three 1-min pulses of 50 mM NaOH and 1 M NaCl at a flow rate of 5 ml/min. N-terminally biotinylated peptides (495% purity) were purchased from Interactiva (Germany). The human TIF2 LXXLL peptide sequences were as follows: Box 1 (residues 636--649), KGQTKLLQLLTTKS and Box 2 (residues 685--698), EKHKILHRLLQDSS. Peptides were immobilized on individual surfaces to 200 RU responses. Samples of purified hERbwt-LBD or hERbV320G-LBD in the presence or absence of estradiol were then injected over each surface. After injection stop, the surfaces were washed with buffer to monitor the dissociation phase. The buffer used was 50 mM Tris--HCl, pH 7.4, hERbV320G shows reduced transcriptional activation in a transactivation assay To test if the identified receptor variants displayed any differences compared with the wild-type receptor with regard to transcriptional activation, a reporter assay was used. We generated plasmids expressing either hERbI3V or hERbV320G under control of the SV40 promoter. The transcriptional activities of the variants were compared with that of the wild-type ERb using an ERE-luciferase reporter system. No differences with regard to transcriptional activation were observed for the hERbI3V variant ( Figure 1A ). However, hERbV320G showed significantly decreased maximal transcriptional activity compared with wild-type ERb ( Figure 1A ). To confirm equivalent ERb expression, extracts from HEK293 cells transfected with equal amounts of the expression vectors for hERbwt, hERbV320G, or hERbI3V were separated by SDS--PAGE and analysed for ERb expression by western blot ( Figure 1B ). This analysis shows that the different ERb derivatives are expressed at similar levels. The observed reduction in maximal transcriptional activity could imply that hERbV320G is defective for interactions with co-factors. Interestingly, as shown in Functional variant of estrogen receptor beta Figure 2 , the amino acid changed in hERbV320G is located on the surface of the receptor protein, quite distant from the ligand-binding pocket.
hERbwt and hERbV320G bind ligands with similar affinity To facilitate a biochemical characterization of hERbV320G, and particularly to compare it to hERbwt, the LBDs of these two proteins were expressed in E.coli and the recombinant proteins were purified. In Figure 3A and B, the results of saturation ligand-binding assays with tritiated estradiol are shown. The measured K d values were 1.50 nM for hERbwt wt and 1.79 nM for hERbV320G (Figure 3) . Affinities for estradiol, tamoxifen and raloxifen, as determined in a competition assay, were also similar for hERbwt and hERbV320G. Thus, the K i s of estradiol, tamoxifen and raloxifen for hERbwt were 0.25, 5.45 and 9.45 nM and for hERbV320G they were 0.33, 5.33 and 10.11 nM, respectively. This is consistent with the position of the variant amino acid distant from the ligandbinding pocket (Figure 2 ).
hERbV320G shows reduced co-factor interaction
Having demonstrated that hERbV320G binds ligands with similar affinity as hERbwt, yet shows significantly reduced maximal transactivation in a reporter assay, we hypothesized that hERbV320G is defective for co-factor interactions. This is consistent with the position of the V320G amino acid change, on the surface of the receptor protein in a region postulated to be involved in co-factor interactions ( Figure 2 ). To test this hypothesis, we performed pull-down assays using purified His-tagged ERb LBDs and 35 S-labeled full-length TIF2 in the presence or absence of estradiol. As shown in Figure 4 , TIF2 bound to hERbwt and hERbV320G in a ligand-dependent manner. Furthermore, the interaction of TIF2 with hERbV320G was weaker than with hERbwt.
To more quantitatively examine TIF2 interaction to hERbV320G and hERbwt, we used the SPR analysis, where biotinylated 14mer peptides containing NR box motifs (LXXLL) from TIF2 were captured via streptavidin to the chip surface. Figure 5 box of TIF2. The result showed that binding of estradiol to ERb enhances the affinity of ERb-peptide interaction. Binding studies were made for the different TIF2 NR box peptides using five to six different concentrations of hERbwt-LBD or hERbV320G-LBD unliganded or liganded with estradiol ranging from 0.25 to 2 mM. Affinity determination analysis was then performed using BIAevaluation software. The curve fitting analysis showed that the model best describing the experimental data was a 1:1 binding with drifting baseline model. The K d for binding to TIF2 box1 was 0.23 AE 0.04 mM (mean AE SD) and 0.52 AE 0.05 mM and K d for binding to TIF2 box2 was 0.39 AE 0.1 mM and 0.79 AE 0.1 mM for hERbwt-LBD and hERbV320G-LBD liganded with estradiol, respectively. The determined affinities show that hERbV320G displays reduced affinity for TIF2 as compared with that of wild-type ERb. Reduced affinity for TIF2 was also seen with unliganded hERbV320G-LBD as compared with unliganded hERbwt-LBD (data not shown).
Discussion
In this paper we identify five novel polymorphisms in the hERb gene in an African population. Interestingly, two of these polymorphisms are expected to change the corresponding amino acid of the encoded ERb protein. These polymorphisms have not been identified in any of the published reports that describe the characterization of polymorphisms in the ERb gene in both Caucasians (n ¼ 502) (27) and Asians (n ¼ 184) (28) . In Africans, the variant protein hERbV320G, encoded by one of these polymorphic ERb genes, displays lower maximal transcriptional activity compared with wildtype ERb. To our knowledge, this represents the first example of a functional polymorphism in the ERb gene. The hERbV320G change results in the amino acid substitution of valine for glycine in helix 4 of the LBD. Helix 4 does not participate directly in binding of the ligand (29) . However, it forms part of the surface that interacts with coactivators (30) . The hERbV320G side chain is in close proximity to K314, which forms half of the charge-clamp of the co-activator-binding pocket. Therefore, the hERbV320G may perturb the conformation of K314, which in turn perturbs cofactor interactions. Consistent with this, we did not find any changes in ligand-binding affinity of hERbV320G. However, this variant displays decreased interaction with the co-activator TIF2. We propose that reduced co-factor interaction is the cause for the observed reduced maximal transactivation.
Several endocrine-related diseases show population-based differences in terms of disease incidence and/or disease progression but the reason for this racial difference is unclear. When compared with white American women, African American women have a higher incidence of breast cancer before the age of 40 years, and the prognosis after a diagnosed breast cancer is reported to be poorer at all ages (31) . Studies have suggested that higher plasma levels of insulin-like growth factor-1 (IGF-1) may account for African American women having higher risk of premenopausal breast cancer than white women and may also be an important determinant of breast cancer risk in postmenopausal women (32--34) . A prolonged exposure to estrogens has been repeatedly found to be associated with an increased risk for breast cancer. Racial disparities in conditions such as postmenopausal obesity, early menarche and late menopause that all increase endogenous levels of estrogens may put an African American woman at a greater risk for breast cancer (35) . African American men present a higher stage of prostate cancer and a worse outcome of this disease than non-African American men (36) . The increased frequency of prostate cancer among African American men has been attributed to either greater plasma levels of testosterone (37) or an increased dihydrotestosterone/testosterone ratio (38) in this population. Previous studies also revealed that the plasma level of IGF-1 might be a predictor of prostate cancer risk (39, 40) . Some of these racial differences could be attributed to population differences in genetic polymorphisms. Polymorphisms involving genes coding for the androgen receptor, phase I/II enzymes and vitamin D receptor have been associated with an increased risk of prostate cancer (41) . Polymorphisms that are associated with breast cancer risk have been identified in the genes involved in a wide variety of functions including steroid hormone metabolism, Functional variant of estrogen receptor beta detoxification of environmental carcinogens and tumor suppressor genes (42) . In this study, we have identified one novel polymorphism in the ERb gene in an African population that showed decreased transcriptional activity. Dysregulation of ERb expression has been reported to be associated with progressions of breast and prostate cancer (43--46) , indicating that ERb functions as a tumor suppressor gene. The hyperplastic prostate (47) and dedifferentiated mammary gland (48) phenotypes displayed by ERb knockout mice support a role for ERb in control of mammary and prostate growth. Further association studies are required to determine whether this polymorphism is involved in the increased incidence of prostate and breast cancers in Africans.
